The latest price target for Renalytix (NASDAQ:RNLX) was reported by HC Wainwright & Co. on July 12, 2024. The analyst firm set a price target for $3.00 expecting RNLX to rise to within 12 months (a possible 883.61% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Renalytix (NASDAQ:RNLX) was provided by HC Wainwright & Co., and Renalytix reiterated their buy rating.

There is no last upgrade for Renalytix

There is no last downgrade for Renalytix.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Renalytix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Renalytix was filed on July 12, 2024 so you should expect the next rating to be made available sometime around July 12, 2025.

While ratings are subjective and will change, the latest Renalytix (RNLX) rating was a reiterated with a price target of $3.00 to $3.00. The current price Renalytix (RNLX) is trading at is $0.31, which is out of the analyst’s predicted range.